ACTIVE HALF-LIFE
5 days
CLASSIFICATION
Dual GIP and GLP-1 Receptor Agonist
MANUFACTURER
Beligas - US
WAREHOUSE
USA Warehouse 2
SUBSTANCE
GIP/GLP-1 RA
Introducing Tirzepatide, a cutting-edge synthetic peptide designed to effectively manage glucose levels. This remarkable compound works by stimulating both the initial and secondary phases of insulin release while simultaneously reducing glucagon levels, all in a glucose-dependent manner.
For individuals with type 2 diabetes, Tirzepatide has proven its effectiveness in slowing gastric emptying, lowering both fasting and post-meal glucose levels, curbing appetite, and promoting weight loss. Additionally, it enhances insulin sensitivity for improved metabolic health.
This unique peptide features a C20 fatty diacid component, strategically linked through a hydrophilic bond at the lysine residue at position 20. This design ensures a robust binding to albumin in the bloodstream, significantly extending its action duration.
Glucagon-like peptide-1 (GLP-1) receptors (GLP-1R) are widely distributed in the body, particularly in pancreatic beta-cells and the gastrointestinal tract. These receptors are crucial in managing type 2 diabetes mellitus, as GLP-1R signaling promotes insulin release in response to glucose, slows gastric emptying, reduces blood glucagon levels, and activates pathways in the brain that help suppress appetite. Furthermore, glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 work together to maintain glucose stability by promoting insulin secretion from pancreatic beta-cells, with GIP being the primary incretin hormone that triggers insulin release upon food intake.
While the precise mechanism of action of Tirzepatide is still under investigation, its dual targeting of GIP and GLP-1R is likely key to its effectiveness in regulating blood sugar and aiding in weight management. Research indicates that the combination of GIP with a GLP-1R agonist yields a stronger insulin response and lower glucagon secretion than administering each hormone independently. Tirzepatide exhibits a high binding affinity for both GIP and GLP-1R, with its affinity for GIP receptors comparable to that of natural GIP, while its GLP-1R affinity is five times lower than that of native GLP-1. By activating the GLP-1R signaling pathway, Tirzepatide enhances insulin release in response to glucose through its interaction with either the GIP receptor (GIPR) or the GLP-1R. However, further research is needed to fully understand the implications of GIPR activation regarding blood glucose control and weight management, as findings in both preclinical and clinical contexts show variability.